Born 1961. Board member since November 2014 and CEO since June 2017.
Anders Weilandt was CEO for Diabetes Tools Sweden AB from 2011-2016. Previously a member of the Board at Stille AB (publ) during the period 2004-2006, and also CEO from 2006-2009. Anders was CEO för Ascendia MedTech AB from 2000-2006. Anders currently has several Board assignments for various different companies. Medical electronics engineer. Anders holds an Executive MBA from Copenhagen Business School, which he acquired in 2004.
Niklas has been CFO for the Chordate Group since October 2017. Niklas works primarily as CFO and Finance Manager in a number of companies, and was previously the CEO for the consultancy company, Driven Ekonomi AB. Niklas holds an MSc in Finance from Stockholm University, which he acquired in 1992.
Born 1956. Clinical Research & Medical Director since January 2012.
Jan is a dentist with over 25 years of experience within the pharmaceuticals industry. Jan was Head of Division and held other managerial posts at AstraZeneca AB between 2001 and 2010, and during the period 1998-2001 was Therapeutic Area Vice President at Pharmacia & Upjohn. During the period 1983-1998, he held a number of managerial posts at Astra AB. Jan worked as a teacher at the Dentistry College in Huddinge during the period 1981-1983. Degree from the School of Dentistry, Karolinska Institute in Stockholm, acquired in 1980.
Born 1956. Head of R&D, Production and Quality since June 2012.
Jan Lindberg has had a long career within the medical technology field. He held a number of leading posts at St. Jude Medical during the period 1988-2012, including Head of Hardware Development and Group Head of Electronics Development. Prior to this he was a developer at Electrolux between 1985 and 1988 and at RIFA AB between 1981 and 1985. While studying he ran his own company from 1977 to 1981. Studied engineering at KTH in Stockholm, 1980.
Born 1974. Regulatory Affairs Manager since June 2023.
Linda has extensive experience in product development within the medtech and pharma industries, with previous assignments at companies such as Sedana Medical AB, AstraZeneca, GE Healthcare, and Cepheid. Linda holds a Master of Science in Pharmaceutical Sciences from Uppsala University and a PhD in Molecular Biology from Karolinska Institutet.
Born 1973. Director of Quality Assurance since June 2023.
Cilla has been working in the medical technology industry since 1997, primarily focusing on development and testing at companies such as Siemens-Elema, St. Jude Medical, and Elekta. In recent years, she has also been involved in quality assurance, serving as a Quality Manager at Directa Dental/Orsing and undertaking various roles as a QA/RA consultant. Cilla holds a Master of Science in Electrical Engineering from the Royal Institute of Technology (KTH) and a Master’s degree in Medical Radiation Physics from Stockholm University.
Born 1980. Process owner, Catheter since June 2023.
Fredrik is originally a mechanical engineer with a specialization in product development and the development of production lines. He has been working as a consultant with a focus on the medical technology industry since 2010, with extended assignments at companies such as AstraZeneca and Masimo Sweden AB. He has previously been involved in sales and development within the Swedish manufacturing industry as well.
We are a Swedish medical technology company listed on Nasdaq First North Growth Market.
Chordate has spent more than 10 years developing the treatment Ozilia™, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia™ in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.